Chávez-López ZD, Hierro-Orozco S

Language: Spanish
References: 21
Page: 35-40
PDF size: 599.35 Kb.

ABSTRACT

Atopic dermatitis is a chronic, recurrent and inflammatory skin disease characterized by intense pruritus. It is considered a disease influenced by genetic, environmental, immunological and non-immunological factors, which play an important role in its etiopathogenesis. Often the treatment for atopic dermatitis in adults becomes frustrating for both the patient and the doctor. The development of new topical and systemic agents for atopic dermatitis could provide a more effective therapy for those patients with poor response to conventional treatments.

REFERENCES

1. Byung E, Leung D. Significance of skin barrier dysfunction in atopic dermatitis. Department of pediatrics National Jewish Health. Allergy Asthma Immunol Res. 2018 May;10(3):207-215.

2. Kennedy E, Connolly J, Hourihane J, et al. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy Clin Immunol 2017;139:166-72.

3. Williams M, Gallo R. The Role of the Skin Microbiome in Atopic Dermatitis. Curr Allergy Asthma Rep (2015) 15: 65

4. Brunner P, Guttman-Yassky E, Leung D. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017;139:S65 76

5. Pelc J, Czarnecka-Operacz M, Adamski Z. Structure and function of the epidermal barrier in patients with atopic dermatitis–treatment options. Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, Poland. Adv Dermatol Allergol 2018.

6. Hanifin J. Adult-Onset Atopic Dermatitis: Fact or Fancy?. Dermatol Clin 35 (2017) 299–302

7. Chopra R, Vakharia P, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017 Nov;177(5):1316-1321.

8. Lynde C, Bourcier M, Gooderham M. Et al. A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Canadian Dermatology Association. J Cutaneous Medicine and Surgery 2017. 1–6.

9. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP phosphodiesterase in atopic disease: a possible mechanism for cyclic AMPagonist hyporesponsiveness. J Allergy Clin Immunol. 1982;70:452-7.

10. Paller A, Tom W, Lebwohl M, Blumenthal R, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Der matol. 2016;75:494-503.

11. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes- Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvantinduced arthritis. J Inflamm (Lond). 2010;7:41.

12. Bissonnette R, Papp K, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902-911.

13. Iyengar S, Hoyte E, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebocontrolled clinical trial. Int Arch Allergy Immunol 2013;162:89-93.

14. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is downregulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126:332-7.

15. Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-tosevere atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebocontrolled phase II trial (TREBLE). J Am Acad Dermatol. 2018 May;78(5):863-871.

16. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Birrell C, Kell C, et al. A phase 2b doseranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2017;76:AB20.

17. Abrouk M, Farahnik B, Zhu T, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017;77:177-180.

18. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Lüscher-Firzlaff J, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129:426-33.

19. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin- 31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med. 2017;376:826-835.

20. Hamilton JD, Suárez-Farińas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-tosevere atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293-1300.

21. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375:2335-48.